- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05724264
SingapOre Lung Cancer Screening Through Integrating CT With Other biomarkErs (SOLSTICE)
This is a single arm screening study. All eligible participants will be subjected to low dose CT (LDCT) screening and biomarker testing.
The primary aim of the study is to determine the feasibility of conducting LDCT screening in at-risk populations for lung cancer in Singapore:
- For the smoker population, LDCT screening for lung cancer will be implemented in accordance to Academy of Medicine, Singapore screening test guidelines with the aim of investigating the feasibility of instituting lung cancer screening clinical service in Singapore.
- For the non-smoker population, LDCT screening for lung cancer will be introduced to systematically collect baseline data to better understand and provide evidence for lung adenocarcinoma in never-smoker phenotype that is unique to East Asia/Singapore. This will help address unmet needs in local population research as reported by Academy of Medicine, Singapore, to validate risk factors and inform future screening guidelines for the at-risk population.
Screening results will be reported based on Lung CT Screening Reporting & Data System (Lung-RADS).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single arm cohort screening study. Briefly, this prospective study will involve screening the general population with risk factors for lung cancers with the aim of investigating the feasibility of implementing LDCT screening in the local context. Both smokers and non-smokers with the known risk factor of family history of lung cancer up to 2nd degree are eligible to participate in the study. Depending on emerging epidemiological data, additional high-risk cohorts may be included in this study. Subject demographics, smoking history, exposure to the aforementioned environmental factors, family history of lung cancer, history of tuberculosis and comorbidity will be captured in detail. The age range for inclusion is 55 to 74 years. Given the higher proportion of never-smoker lung cancer in Singapore, we aim to recruit 650 non-smoking and 350 smoking individuals for our study.
LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.
Participants with LDCT scan results of Lung-RADS score 2 and above will be referred to the nodule clinic under SingHealth DUKE-NUS Lung Centre for standardized follow-ups and/or diagnostic evaluation. These patients will undergo clinical surveillance (up to maximum of 5 years depending on their nodules) and will be managed as per current clinical practice. Participants with LDCT scan results of Lung-RADS score of 1 will undergo further screening surveillance which will end after 2 years if they have no nodules detected.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Darren Wan-Teck Lim, MD
- Phone Number: 64368000
- Email: darren.lim.w.t@singhealth.com.sg
Study Contact Backup
- Name: Gillianne Geet-Yi Lai, MD
- Phone Number: 64368000
- Email: gillianne.lai.g.y@singhealth.com.sg
Study Locations
-
-
-
Singapore, Singapore, 169609
- Recruiting
- National Heart Centre Singapore
-
Singapore, Singapore, 169608
- Recruiting
- Singapore General Hospital
-
Singapore, Singapore, 168583
- Recruiting
- National Cancer Centre, Singapore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Smoker:
- Participant is willing and able to give informed consent for participation in the study
- Male or female, aged 50-80 years of age
- No prior history of cancer, or cancer free in the last 5 years and not currently on cancer treatment
- ECOG 0/1
- Current or former smokers with at least 30 pack years of smoking history
- Willing to comply with study follow-up schedule and tests
- Willing to cover the costs of downstream standard of care management and investigations including doctor's fee, CT scan and biopsy etc.
- A Singapore citizen/Permanent Resident of Singapore
Non-Smoker:
- Participant is willing and able to give informed consent for participation in the study
- Male, or female, aged 50-80 years of age
- No prior history of cancer, or cancer free in the last 5 years and not currently on cancer treatment
- ECOG 0/1
- Never smoker, or has smoked less than 10 pack-years and has quit smoking for at least 15 years
- Family history of lung cancer up to 2nd degree relatives
- Willing to comply with study follow-up schedule and tests
- Willing to cover the costs of downstream standard of care management and investigations including doctor's fee, CT scan and biopsy etc.
- A Singapore citizen/Permanent Resident of Singapore
Exclusion Criteria:
- Uncontrolled medical comorbidity on enrolment
- Previous diagnosis of cancer
- Bleeding diathesis that will preclude blood sampling
- Fear of blood draw or needles
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low-dose CT of the Chest (LDCT) + Blood sampling
|
LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants. All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of conducting Low Dose CT (LDCT) screening in at-risk populations (1).
Time Frame: At Baseline.
|
Diagnostic accuracy of LDCT at baseline.
|
At Baseline.
|
Feasibility of conducting LDCT screening in at-risk populations (2).
Time Frame: Up to 2 years after Baseline.
|
Compliance with LDCT screens for patients with lung-RADS 1 from baseline till end of screening surveillance.
|
Up to 2 years after Baseline.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The utility of blood-based biomarker assays in improving the performance of LDCT to detect lung cancer and discriminate risk of malignancy. (1)
Time Frame: Up to 7 years after Baseline.
|
Diagnostic accuracy and discrimination ability of biomarker assay in the detection of lung cancer will be assessed via sensitivity, specificity, PPV, NPV and area under curve (AUC) of the receiver operating characteristic curve.
|
Up to 7 years after Baseline.
|
The utility of blood-based biomarker assays in improving the performance of LDCT to detect lung cancer and discriminate risk of malignancy. (2)
Time Frame: Up to 7 years after Baseline.
|
Changes in biomarker levels over time in relation to lung cancer diagnosis.
Time series plot of biomarker levels by whether participants have lung cancer diagnosed will be created.
Linear mixed effect models will be used to assess the changes in biomarker levels over time in the group of participants with lung cancer diagnosed, and to compare whether the changes observed are different from those experienced by the group of patients with no lung cancer diagnosed.
|
Up to 7 years after Baseline.
|
Comparison of the diagnostic performance of each combination of a biomarker assay and LDCT screening against that of LDCT screening.
Time Frame: Up to 7 years after Baseline.
|
A biomarker assay that can accurately diagnose lung cancer will then be combined with LDCT screening via a re-definition of what constitute a positive screening test (e.g.
Lung-RADS 3 to 4X or biomarker assay above a certain threshold).
The additional diagnostic value of a biomarker assay will be assessed by comparing the diagnostic performance of the combination of the biomarker assay and LDCT screening against that based on LDCT screening alone.
|
Up to 7 years after Baseline.
|
The lung cancer detection rate at each round of screening.
Time Frame: Up to 2 years after Baseline.
|
Screen detected lung cancer rate at baseline, and interval cancers detected between screening rounds.
|
Up to 2 years after Baseline.
|
The morbidity of LDCT screening.
Time Frame: Up to 2 years after Baseline.
|
Adverse events relating to LDCT screening.
|
Up to 2 years after Baseline.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate if computer-aided diagnosis strategies can enhance LDCT screening.
Time Frame: Up to 2 years after Baseline.
|
Identification of radiomic biomarkers that can improve the diagnostic accuracy of LDCT screening.
Screening LDCT imaging data as well as data from subsequent staging imaging studies of participants with proven screening-detected lung cancer will be evaluated.
The lung tumour(s) will be segmented and quantitative features extracted using semi-automated software systems.
The extracted quantitative features will be analysed in combination with clinical and pathological data to develop models that predict tumour characteristics or treatment response.
|
Up to 2 years after Baseline.
|
To determine the feasibility of screening for concomitant coronary artery disease.
Time Frame: Up to 2 years after Baseline.
|
LDCT-based calcium scoring in cardiovascular disease risk assessment.
|
Up to 2 years after Baseline.
|
To study gene-environment-lifestyle interactions in the screened population.
Time Frame: Up to 7 years after Baseline.
|
For gene-environment-lifestyle interaction analysis, interactions between genetic variants (by means of genotyping of samples collected) and environmental risk factors (gathered from Life-Style questionnaire administered) will be assessed using a 2 degree of freedom joint test, which provides a joint test for genotype and genotype-environment interaction terms.
GWAS association tests will be performed using significant SNPs that were previously reported in the literature and combined with questionnaire data on environmental exposures and lifestyles.
All statistical analyses will be conducted using R version 3.5.
All tests are considered significant with a p-value of less than 0.06.
False discovery rates (FDR) will be calculated using the Benjamini and Hochberg method to account for multiple comparisons.
|
Up to 7 years after Baseline.
|
To determine cost-effectiveness of LDCT screening for early diagnosis.
Time Frame: Up to 7 years after Baseline.
|
Quality-adjusted life-years (QALYs) gained.
|
Up to 7 years after Baseline.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Darren Wan-Teck Lim, MD, National Cancer Centre, Singapore
- Principal Investigator: Gillianne Geet-Yi Lai, MD, National Cancer Centre, Singapore
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020/2962
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays
-
Far Eastern Memorial HospitalCompleted
-
Postgraduate Institute of Medical Education and...Completed
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingLung CarcinomaUnited States
-
University Hospital, GenevaOspedale Regionale di Lugano; Insel Gruppe AG, University Hospital BernRecruitingPneumonia | Elderly InfectionSwitzerland
-
Groupe Hospitalier de la Region de Mulhouse et...RecruitingLung Cancer | High-Risk CancerFrance
-
Assistance Publique - Hôpitaux de ParisNational Cancer Institute, France; Ministère de la Santé et des SolidaritésRecruitingLung Cancer ScreeningFrance
-
Centre Hospitalier Universitaire de NīmesRecruitingHead Injuries, Closed | Head Injuries, PenetratingFrance
-
Université de SherbrookeCompletedAscendant Aortic AneurysmCanada
-
Duke UniversityCompletedShoulder ArthroplastyUnited States